Cytran
Quick facts
Phase 3 pipeline
- IM862 · Oncology
IM862 is an immunomodulatory agent that enhances immune function through interleukin-2 (IL-2) pathway activation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: